Current options in treatment of anthracycline-resistant breast cancer

Cancer Treatment Reviews

Volumn 25, Issue 5, 1999, Pages 279-291

  Kroger N ^a   Achterrath, W ^a   Hegewisch Becker, S ^a   Mross, K ^a   Zander, A R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anthracycline resistance; Breast cancer; Resistance modulation; Taxoid

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DEXVERAPAMIL; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUTATHIONE; GLYCOPROTEIN P; GROWTH FACTOR; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; QUINIDINE; TAXANE DERIVATIVE; VERAPAMIL; VINBLASTINE; VINCRISTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; DRUG CHOICE; DRUG EFFICACY; DRUG TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PROGNOSIS; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0344678381     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0137     Document Type: Review

References (115)

1. Tormey D. C. Adriamycin in breast cancer: an overview of studies. Cancer Chemother Rep. 6:1975;319-327.
2. Carmo-Pereira J., Costa F. O., Henriques E. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer. 56:1987;471-473.
3. Bronchud M. H., Howell A., Crowther D. The use of granulocyte colony stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 60:1989;121-125.
4. Henderson I. C. Chemotherapy for metastatic disease. Harris J. R., Hellmann S., Henderson I. C., Kinne D. W. Breast disease. 1991;601-665 Lippincott, Philadelphia.
5. Coukell A. J., Folds D. Epirubicin. Drugs. 3:1997;453-483.
6. Buzdar A. U., Legha S. S., Hortobagyi G. N. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer. 47:1981;1798-2802.
7. Stewart D. J., Raphorst G. P., Yau J. Active vs passive resistance, dose-response relationships, high-dose chemotherapy, and resistance modulation: a hypothesis. Investigational New Drugs. 14:1996;115-130.
8. Hegewisch-Becker S., Staib F., Löning T. No evidence for the expression of a functional multidrug resistance gene product in primary human breast cancer. Ann Oncol. 9:1998;85-93.
9. Cole S. P. C., Bhardwaj G., Gerlach J. H. Overexpression of a transporter gene in a multidrug resistance human lung cancer cell line. Science. 258:1992;1650-1654.
10. Nooter K., Brutel de la Riviere G., Look M. P. The prognostic significance of expression of the multi-drug resistance associated protein (MP) in primary breast cancer. Br J Cancer. 76:1997;486-493.
11. Filipits M., Suchomel R. W., Dekan G. MRP and MDR1 gene expression in primary breast carcinoma. Clinical Cancer Research. 2:1996;1231-1237.
12. Loflin P. T., Zwelling L. A. Topoisomerase II and the path of apoptosis. Contemp Oncol. 11:1994;46-57.
13. Keith W. N., Douglas F., Wishart G. C. Co-amplification of erb B2, topoisomeraseII, alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer. 29A:1993;1469-1475.
14. Kim R., Hirabayashi N., Nishiyama M. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res. 11:1991;429-431.
15. Batist F., Tulupe A., Sinha B. K. Overexpression of a novel amionic transferase in multidrug resistant human breast cancer cells. J Biol Chem. 261:1986;15544-15549.
16. Molina R., Osterrich S., Zhou J. L. Glutathione transferase GST-pi in breast tumours evaluated by three techniques. Dis Markers. 11:1993;71-82.
17. Gianni L. Anthracycline Resistance: The problem and its current definition. Seminars in Oncology. 24:1997;10-11.
18. Lehnert M., Mross K., Schueller J. Phase II trial of Dexverapamil in patients with non-responsive metastatic breast cancer. Br J Cancer. 77:1998;1155-1163.
19. van Kalken C. K., van dHoeven J. J. M., Giaccone G. Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer. 26(6):1991;739-744.
20. Wishart G. C., Bisset D., Paul J. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol. 12:1994;1771-1777.
21. Mross K., Bohn C., Edler L. Randomized phase II study of single agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. Ann Oncol. 4:1993;45-50.
22. Bates S., Meadows B., Goldspiel B. R. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. Cancer Chemother Pharmacol. 35:1995;457-463.
23. Ries F., Dicato M. Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continous infusion of verapamil. A phase I-II clinical trial. Med Oncol & Tumor Phrmacothr. 8:1991;39-43.
24. Mross K., Kröger N., Herbst. Alteration of epirubicin pharmacokinetics and metabolism by dexverapamil: results of phase II study of patients with breast cancer patients to modulate multidrug resistance. Onkologie. 22:1999;35-40.
25. Rushing D. A., Raber S. R., Rodvold K. A. The effect of cyclosporin on the pharmacokinetics of doxorubicin in patients with small lung cancer. Cancer. 74:1994;834-842.
26. Nabholtz J. M., Senn H. J., Bezwoda W. R. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline - containing chemotherapy. J Clin Oncol. 17:1999;1413-1424.
27. Neidhart J. A., Gochnour D., Roach R. A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol. 4:1986;672-677.
28. Henderson I. C., Allegra J. C., Woodcock T. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 7:1989;560-571.
29. Catimel G., Chauvin F., Guastalla J. P. FAC as a second line chemotherapy in patients with metastatic breast cancer progressing under FEC. Ann Oncol. 5:1994;95-97.
30. Brambilla C., Rossi A., Boufante V. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep. 70:1986;261-266.
31. Basthold L., Dalmark M., Gjedde S. B. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a andomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 14:1996;1146-1155.
32. Sledge G. W. Etoposide in the management of metastatic breast cancer. Cancer. 67:1991;266-270.
33. Schell F. C., Yap H. Y., Hortobagyi G. Phase II study of VP16 in refractory metastatic breast cancer. Cancer Chemother Pharmacol. 7:1982;223-225.
34. Martin M., Lluch A., Casado A., Santabarbara P. Clinical activity of chronic oral Etoposide in previously treated metastatic breast cancer. J Clin Oncol. 12:1994;986-991.
35. Crooke S. T., Bradner V. T., Mitomycin C. a review. Cancer Treat Rev. 3:1976;121-139.
36. Creech R. H., Catalano R. B., Mukund K. An effective low dose Mitomycin regimen for hormonal and chemotherapy refractory patients with metastatic breast cancer. Cancer. 51:1983;1034-1040.
37. Dieras V., Marty M., Tubiana N. Phase II randomized study of Paclitaxel versus Mitomycin in advanced breast cancer. Sem Oncol. 22 (4):1995;33-39.
38. Jones S., Winer E., Vogel C. Randomized comparison of Vinorelbine and Melphalan in anthracycline refractory advanced breast cancer. J Clin Oncol. 13:1995;2567-2574.
39. Yap H. Y., Salem P., Hortobagyi G. N. Phase II study of cisdichloroplatinum in advanced breast cancer. Cancer Treat Rep. 19:1978;347.
40. Kolaric K., Roth A. A phase II clinical trial of cis-dichlorodiammine platinum for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 11:1983;108-112.
41. Garufi C., Nisticö C., Brienza S. Oxaliplatin activity in anthracycline resistant metastatic breast cancer patients. Proc Am Soc Clin Oncol. 1997;595.
42. Carter S. K. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev. 3:1976;141-174.
43. Falcone A., Cianci C., Pfanner E. Continuous infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance (letter). Ann Oncol. 5:1994;291.
44. Jabboury K., Holmes F. A., Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer. 64:1989;793-797.
45. Hansen R., Quebbeman E., Beatty P. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat. 10:1987;145-149.
46. Wilke H., Klaassen U., Achterrath W. Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus highdose folinic acid in intensively pretreated patients with metastatic breast cancer. Ann Oncol. 7:1996;55-58.
47. Zaniboni A., Arcangeli G., Meriggi F. Low dose leukovorin and 5-FU salvage treatment in metastatic breast cancer. Proc Am Soc Clin Oncol. 1994;165.
48. Carmichael J., Possinger K., Phillip P. Advanced breast cancer: A phase II trial with Gemcitabine. J Clin Oncol. 13:1995;2731-2736.
49. Spielmann M., Pouillart P., Espie M. Activity of Gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens. Ann of Oncol. 7(suppl 5):1996;99.
50. Hansen P. V., Brincker H. Vindesine in the treatment of metastatic breast cancer. Eur J Cancer. 20:1984;1221-1225.
51. Yau J. C., Yap Y. Y., Buzdar A. U., Hortobagyi G. N. A comparative randomized trial of vinca-alkaloids in patients with metastatic breast carcinoma. Cancer. 55:1985;337-340.
52. Ingle J. N., Ahmann D. L., Gerstner J. G. Evaluation of Vinblastine administered by 5 days continuous infusion in women with advanced breast cancer. Cancer Treat Rep. 68:1984;803-804.
53. Tannock I., Ehrlichman C., Perrault D. Failure of 5-day Vinblastine infusion in the treatment of advanced refractory breast cancer. Cancer Treat Rep. 66:1982;1783-1784.
54. Dogliotti L., Gorzegno G., Bau M. G. Vinorelbine as second line treatment in anthracycline pretreated advanced breast cancer patients: a phase II study. Eur J Cancer. 29A (:1993;430.
55. Barni S., Frontini L., Villa S. Vinorelbine in pretreated advanced breast cancer. Eur J Cancer. 29A (suppl 6):1993;418.
56. Degardin M., Bonneterre J., Hecquet B. Vinorelbine as salvage treatment for advanced breast cancer. Ann Oncol. 5:1994;423-426.
57. Clemons M., Leahy M., Valle J. Review of recent trial of chemotherapy for advanced breast cancer: the taxanes. Eur J Cancer. 13:1997;2183-2193.
58. Reichman B. S., Seidman A. D., Crown J. P. A. Paclitaxel and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 11:1993;1943-1951.
59. Constenia M., Garcia-Arroyo F. R. Phase II trial of paclitaxel 96-hour infusion with G-CSF in anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol. 16:1997;574.
60. Verweij J., Clavel M., Chevalier B. Paclitaxel and Docetaxel: Not simply two of a kind. Ann Oncol. 5:1994;495-505.
61. Chevalier B., Fumoleau P., Kerbat P. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 13:1995;314-322.
62. Seidman A. D., Reichman B. S., Crown J. P. A. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol. 13:1995;1152-1159.
63. Wilson W. H., Berg S. L., Bryant G. Paclitaxel in doxorubicin-refractory or mitoxantrone refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 12:1994;1621-1629.
64. Abrams J. S., Vena D. A., Baltz J. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol. 13:1995;2056-2065.
65. Nabholtz J. M., Gelmon K., Bontenbal M. Multicenter, randomized comparative study of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 14:1996;1858-1867.
66. Munzone E., Capri G., Demichelli R. Activity of taxol by 3 h infusion in breast cancer patients with clinical resistance to anthracyclines. Eur J Cancer. 29A:1993;413.
67. Vermorken J. B., ten Bokkel Huinink W. W., Mandjes I. A. M. High-dose paclitaxel with granulocyte colony stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy. A European Cancer Center trial. Sem Oncol. 13:1995;2056-2065.
68. Valero V., Holmes F. A., Walters R. S. Phase II trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 13:1995;2886-2894.
69. Ravdin P. M., Burris H. A. III, Cook G. Phase II Trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 13:1995;2879-2885.
70. Guastalla J. P., Bonneterre J., Fumoleau P. A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer. Eur J Cancer. 31A:1995;348.
71. Pierre S. G., Hupperets J., Fickers M. M. F. Phase II study with mitomycin and vindesine in metastatic pretreated breast cancer. Eur J Cancer. 27:1991;520-521.
72. Millward M. J., Hendrik A., Cantwell B. M. J. Fixed dose short course mitomycin C with vincristine in advanced pretreated breast cancer. Ann Oncol. 1:1990;373-374.
73. Belpomme D., Heritier F., Gisselbrecht C. Long duration of response with vindesine-mitoxantrone-mitomycine combination chemotherapy in metastatic breast cancer. A pilot phase II study. Cancer Treat Rep. 71:1987;845-847.
74. Konits P. H., Aisner J., van Echo D. A. Mitomycin C and vinblastin chemotherapy for advanced breast cancer. Cancer. 48:1981;1295-1298.
75. Denefrio J. M., East D. R., Troner M. B. Phase II study of mitomycin C and vinblastin in women with advanced breast cancer refractory to standard cytotoxic therapy. Cancer treatment reports. 62:1978;2113-2115.
76. Fabi A., Tonachella R., Savarese A. A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann Oncol. 6:1995;187-189.
77. Bishop J. F., Raghavan D., Woods R. Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. Cancer Treat Rep. 71:1987;191-193.
78. Perrone F., DePlacido S., Carlomagno C. Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. Am J Clin Oncol. 17:1994;218-222.
79. Fraschini G., Holmes F. A., Buzdar A. U. Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer. Am J Clin Oncol. 11:1988;448-450.
80. Paridaens R., Clarysse A., Rozencweig M. Cisplatin plus vindesine in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group. Eur J Cancer. 21:1985;595-599.
81. Giaccone G., Donadio M., Ferrati P. Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer. Tumori. 74:1988;191-193.
82. Rowinsky E. K., Donehower R. C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmac Ther. 52:1991;35-84.
83. Pazdur R., Kudelka A. P., Kavanagh J. J. The taxoids:paclitaxel and docetaxel. Cancer Treat Rev. 19:1993;351-386.
84. Bitran J. D., Kozloff M. F., Desser R. K. Platinol and continous intravenous infusion 5-FU in refractory stage IV breast cancer: a phase II study. Cancer Investigtion. 8:1990;335-338.
85. Jaobs S. A., Stoller R. G., Earle M. F. 96-hour 5-fluorouracil infusion plus DDP in advanced breast cancer. Proc Am Soc Clin Oncol. 4:1985;71.
86. Fountzilas G., Athanassiadis A., Kaloger-Fountzila A. Paclitaxel by 3 h infusion and carboplatin in anthracycline resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer. 33:1997;1893-1895.
87. Bernard A., Antoine E. C., Gozy M. Docetaxel and cisplatin combination in anthracycline-pretreated advanced breast cancer. Preliminary results of a phase II study. Breast Cancer Research and Treatment. 46:1997;229.
88. Llombart-Cussac A., Spielmann M., Dohollou N. Cisplatinum-Taxotere phase I/II trial in patients with anthracycline-resistant advanced breast cancer. Proc Am Soc Clin Oncol. 16:1997;629.
89. Klaassen U., Wilke H., Harstrick A. Paclitaxel in combination with weekly high dose 5-FU/folinic acid in the second line treatment of metastatic breast cancer. Ann Oncol. 9:1998;45-50.
90. Klaassen U., Wilke H., Strumberg D. Paclitaxel combinations with weekly high-dose 5-FU/FA and cisplatin in treatment of metastatic breast cancer. Eur J Cancer. 32:1996;7-18.
91. Schabel F. N. Jr, Griswold D. P. Jr, Corbett T. H. Increasing therapeutic response rate to anticancer drugs by applying the basic principles of pharmocology. Pharmacol Therapeut. 20:1983;283-305.
92. Teicher B. A., Cucchi C., Lee J. Alkylating agents. In vitro studies of cross-resistance patterns in human tumor cell lines. Cancer Res. 46:1986;4379-4383.
93. Skipper, H. Data and analysis having to do with the influence of dose intensity and duration of treatment on lethal toxicity and the therapeutic response of experimental neoplasms, Booklets 13, 1986 and 2-13,1987, Birmingham, Southern Research Institute.
94. Fields K. K., Partyka J. S., Perkins J. B. Cyclophosphamide and Taxol is an active salvage regimen in patients with anthracycline refractory metastatic breast cancer. Proc Am Soc Clin Oncol. 16:1997;588.
95. Maraninchi D., Gastuat J. A., Herve P. High-dose melphalan and autologous bone marrow transplantation in adult solid tumors: clinical response and preliminary evaluation of different strategies. McVie J. G., Dalesio O., Smith I. E. Autologous bone marrow transplantation and solid tumors. 1984;145-150 Raven Press, New York.
96. Knight W. A., Page C. P., Kuhn J. G. High-dose L-PAM with autologous bone marrow infusion for advanced, steroid hormone receptor negative breast cancer. Breast Cancer Res Treat. 4:1984;330.
97. Lazarus J., Herzig R., Graham Pole J. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol. 2:1983;359-367.
98. LeMaistre C. F., Herzig G. P., Herzig R. H. High-dose thiotepa and autologous bone marrow rescue for treatment of refractory breast cancer. Breast Cancer Res Treat. 40:1987;89.
99. Lazarus H. M., Reed M., Spitzer T. R. High-dose thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep. 71:1987;689-695.
100. Kröger N., Zschaber R., Krüger W. Dose intensity of chemotherapy in breast cancer. Results of clinical studies. Onkologie. 18:1995;419-428.
101. Perkins J. B., Fields K. K., Elfenbein G. J. Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: Evaluation of dose-response relationships. Sem Oncol. 22:1995;7:5-7.
102. Fields K. K., Elfenbein G., Perkins J. B. Two novel high-dose treatment regimens for metastatic breast cancer - Ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: Outcomes and toxicities. Sem Oncol. 20(Suppl 6):1993;59-66.
103. Wallerstein R., Spitzer G., Dunphy F. A phase II study of Mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol. 11:1990;1782-1788.
104. Martino S., Samal B. A., Yoshida S. A phase II study of cis-Diamminechloroplatinum II for advanced breast cancer. J Cancer Res Clin Oncol. 108:1984;354-356.
105. Cobleigh M. A., Williams S., Einhorn L. H. Phase II study of vindesine in patients with metastatic breast cancer. Cancer Treat Rep. 65:1981;659-663.
106. Cox E. B., Burton G. V., Olsen G. A. Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am J Clin Oncol. 12(1):1989;53-56.
107. Fumoleau P., Delgado F. M., Delozier T. Phase II trial of weekly intravenous vinorelbine in first line adanced breast cancer chemotherapy. J Clin Oncol. 11:1993;1245-1252.
108. Garcia-Conde J., Lluch A., Martin M. Phase II trial of weekly IV vinorelbine in first line advanced breast cancer. Ann Oncol. 5:1994;854-857.
109. Blum J. L., Buzdar A. U., LoRusso P. M. A multicenter phase II study of capecitabine in paclitaxel refractory metastatic breast cancer. Proc Am Soc Clin Oncol. 17:1998;476.
110. O'Reilly S. M., Moiseyenko V., Talbot D. C. A randomized phase II study of capecitabine vs paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc Am Soc Clin Oncol. 17:1998;627.
111. Gamucci T., Piccart M., Brüning P. Single agent taxol versus doxorubicine as first line chemotherapy in advanced breast cancer. Final results of an EORTC randomized study with cross-over. Proc Am Soc Clin Oncol. 17:1998;428.
112. Ray-Coquard I., Biron P., Bachelot T. Vinorelbine and cisplatin for treatment of metastatic breast carcinoma after failure of anthracycline and/or paclitaxel contining regimens. Cancer. 82:1998;134-140.
113. Sjöström J., Blonqvist C., Mouridsen M. Docetaxel compared with sequential Methotrexate and 5 FV in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with cross-over on progression by the Scandinavian Breast Group. Eur J Cancer. 35:1999;1194-1204.
114. Warner E., Hedley D., Andrulis I. Phase II study of Dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clinical Cancer Research. 4:1998;1451-1457.
115. Holmes F. A., Valero V., Buzdar A. U. Final result: Randomized phase III trial of paclitaxel by 3 h vs 96 h infusion in pts with metastatic breast cancer. Proc Am Soc Clin Oncol. 17:1998;426.